Internal Medicine Alert – July 30, 2024
July 30, 2024
View Issues
-
Empagliflozin Post-Acute Myocardial Infarction
A prespecified further analysis of the EMPACT-MI trial has shown that patients within two weeks of an acute myocardial infarction who are at risk for heart failure who receive empagliflozin compared to placebo have significantly fewer episodes of heart failure hospitalizations over a median follow-up of 18 months.
-
Is Artificial Intelligence Coming for Your Job?
A retrospective analysis of plain chest X-ray images in the medical record using deep learning in patients suitable for risk assessment for atherosclerotic cardiovascular disease (ASCVD) has shown similar results as the American College of Cardiology/American Heart Association ASCVD risk calculator for determining who is at sufficient risk to consider statin therapy.
-
Racial Inequities in Shared Decision-Making for Critically Ill Patients
In this thematic analysis of a previously conducted randomized clinical trial, disparate shared decision-making behaviors were observed among meetings with white vs. Black caregivers of critically ill patients, illustrating opportunities for future clinician-level interventions.
-
Elafibranor Tablets (Iqirvo)
The U.S. Food and Drug Administration has approved an oral dual peroxisome proliferator-activated alpha and delta receptor agonist for the treatment of primary biliary cholangitis, formerly known as primary biliary cirrhosis. Elafibranor was granted an accelerated approval and an orphan designation.